ArticleCancer cell2025

A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis.

Jin Qian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.